The global biopharmaceutical contract manufacturing market is projected to grow from USD 22.40 billion in 2025 to USD 34.15 billion by 2030, advancing at a CAGR of 8.8% during the forecast period. This growth is being driven by strategic partnerships, industrial collaborations in drug discovery, and advancements in biomanufacturing technologies.
As pharmaceutical and biotech companies increasingly focus on innovation and speed-to-market, outsourcing to contract development and manufacturing organizations (CDMOs) has become a critical enabler of efficiency, scalability, and compliance.
Key Growth Drivers
Several factors are fueling the expansion of the biopharmaceutical contract manufacturing industry:
- Strategic Collaborations & Partnerships: Pharmaceutical firms are entering alliances with CDMOs to accelerate drug discovery, development, and commercialization.
- Technological Advancements: Innovations in cell & gene therapy manufacturing, bioconjugation, and continuous bioprocessing are reshaping the contract manufacturing landscape.
- Cost & Risk Sharing: Outsourcing allows biopharma companies to reduce capital expenditure on infrastructure and mitigate operational risks.
- Personalized Medicine Demand: Rising demand for biologics, biosimilars, and cell-based therapies is driving the need for specialized contract manufacturing capabilities.
Download an Illustrative overview:
Market Landscape: Consolidation at the Top
The biopharmaceutical contract manufacturing market is highly consolidated, with five major players—Lonza (Switzerland), WuXi Biologics (China), Thermo Fisher Scientific Inc. (US), Samsung Biologics (South Korea), and AbbVie (US)—together commanding nearly 50–55% of global revenues.
These players differentiate themselves through advanced technologies, global production networks, and strategic investments. The remaining 45–50% of the market is captured by emerging biotech manufacturers and regional CDMOs, which are growing through niche expertise, partnerships, and technological innovation.
Leading Companies in Biopharmaceutical Contract Manufacturing
- Lonza (Switzerland)
Lonza is widely recognized as a global leader, offering end-to-end solutions across biologics, biosimilars, and advanced therapies. Its robust capabilities span from biologic drug substances to cGMP cell & gene therapy production.
- WuXi Biologics (China)
WuXi Biologics has rapidly expanded its global footprint, serving as a trusted partner for biopharma companies worldwide. The company offers services from drug discovery to commercial manufacturing, supported by large-scale capacity.
- Thermo Fisher Scientific Inc. (US)
Thermo Fisher is a global powerhouse in drug development, clinical trial support, and complex biologics manufacturing.
- Samsung Biologics (South Korea)
Samsung Biologics has built a reputation as one of the fastest-growing biopharmaceutical CDMOs globally.
- AbbVie Inc. (US)
AbbVie combines therapeutic innovation with advanced biologics manufacturing, leveraging its extensive R&D and production capabilities.
Other Notable Players
Beyond the top five, several global and regional companies play an important role in shaping the market:
- Catalent, Inc. (US) – Specializes in drug delivery technologies and biologics manufacturing.
- Boehringer Ingelheim (Germany) – Offers biopharmaceutical contract development and production of therapeutic proteins.
- FUJIFILM Holdings (Japan) – Expanding capabilities in cell & gene therapy CDMO services.
- GenScript Biotech (US) – Strong expertise in synthetic biology and biologics development.
- Eurofins Scientific (Luxembourg) – Provides testing and analytical services alongside contract manufacturing.
These players, along with AGC Inc., JSR Corporation, Ajinomoto Bio-Pharma, Agilent Technologies, and Asahi Kasei Corporation, are strategically investing in expansion, collaborations, and technology integration to strengthen their positions.
Future Outlook
The future of the biopharmaceutical contract manufacturing market will be defined by:
- Expansion of cell & gene therapy CDMO services to meet rising demand.
- AI and digital bioprocessing technologies that enable predictive manufacturing.
- Global footprint expansion to serve pharmaceutical companies across multiple geographies.
- Sustainability initiatives in biomanufacturing to align with ESG goals.
Conclusion
The biopharmaceutical contract manufacturing market is evolving rapidly, with global leaders like Lonza, WuXi Biologics, Thermo Fisher, Samsung Biologics, and AbbVie driving consolidation and innovation. At the same time, regional players are carving niches through specialization and partnerships. With strong growth prospects fueled by technological advancements, personalized medicine, and strategic collaborations, the industry is set to remain a cornerstone of global biopharmaceutical development.